|Year : 2019 | Volume
| Issue : 3 | Page : 448-449
Utility of Xpert® MTB/RIF in the diagnosis of extrapulmonary tuberculosis
Vidya Krishna1, Ram Gopalakrishnan2, Anil Tarigopula3, Senthur Nambi Panchatcharam2, Suresh Kumar Dorairajan2, Ramasubramanian Venkatasubramanian2
1 Department of Infectious Diseases, Sri Ramachandra Medical Centre, Chennai, Tamil Nadu, India
2 Department of Infectious Diseases, Apollo Hospitals, Chennai, Tamil Nadu, India
3 Molecular Diagnostics Laboratory, Apollo Hospitals, Chennai, Tamil Nadu, India
|Date of Submission||19-Sep-2019|
|Date of Decision||27-Oct-2019|
|Date of Acceptance||27-Oct-2019|
|Date of Web Publication||29-Jan-2020|
Dr. Vidya Krishna
A-15, Sterling Ganges, 214, Mount Poonamallee Road, Kattupakkam, Chennai - 600 056, Tamil Nadu
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Krishna V, Gopalakrishnan R, Tarigopula A, Panchatcharam SN, Dorairajan SK, Venkatasubramanian R. Utility of Xpert® MTB/RIF in the diagnosis of extrapulmonary tuberculosis. Indian J Med Microbiol 2019;37:448-9
|How to cite this URL:|
Krishna V, Gopalakrishnan R, Tarigopula A, Panchatcharam SN, Dorairajan SK, Venkatasubramanian R. Utility of Xpert® MTB/RIF in the diagnosis of extrapulmonary tuberculosis. Indian J Med Microbiol [serial online] 2019 [cited 2020 Apr 9];37:448-9. Available from: http://www.ijmm.org/text.asp?2019/37/3/448/274087
In most studies on Xpert® MTB/RIF assay in extrapulmonary tuberculosis (EPTB), it has usually been compared to culture, which is known to be a suboptimal reference standard for EPTB., We share the results of our retrospective study on patients ≥18 years with suspected EPTB between January and July 2015, in which we compared Xpert® MTB/RIF to a composite reference standard (CRS). Patients with proven alternate diagnosis, those with incomplete records and who died or were lost to follow-up within 3 months of starting antituberculous therapy (ATT) were excluded from the study. The patients were classified based on CRS as follows: confirmed TB (microbiologically confirmed), probable TB (clinical symptoms, radiological findings and/or histology/cytology suggestive of TB, no microbiological evidence), possible TB (follow-up indicated response to empirical ATT after 3 months) and not TB (proven alternate diagnoses).
After exclusion, 225 (75 confirmed and 150 probable) of 752 patients with EPTB were included in the study analysis [Figure 1]. Samples included pus (31, 13%), tissue (144, 61%), fluids (40, 17%) and cerebrospinal fluid (20, 8.5%). The rates of culture and Xpert® MTB/RIF positivity in different samples are depicted in [Table 1]. Xpert® MTB/RIF was positive in 68.5%, smear in 11.2% and culture in 35.6% of the cases.
Xpert® MTB/RIF had better sensitivity than cultures for all body sites, especially for lymph node and osteo-articular TB. It had greater sensitivity in tissues than fluids in the diagnosis of pleural and abdominal TB (74% vs. 22%). In all patients with alternate diagnoses, Xpert® MTB/RIF assay was negative. The sensitivity of Xpert® MTB/RIF to identify rifampicin resistance was 100% but specificity was 84.5%.
In conclusion, Xpert® MTB/RIF assay detected >2/3rd of EPTB cases, was 100% specific and almost twice as sensitive as mycobacterial culture. Our findings support the WHO recommendations to routinely use Xpert® MTB/RIF assay in the diagnosis of EPTB.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| ~ References|| |
Maynard-Smith L, Larke N, Peters JA, Lawn SD. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: A systematic review. BMC Infect Dis 2014;14:709.
Penz E, Boffa J, Roberts DJ, Fisher D, Cooper R, Ronksley PE, et al.
Diagnostic accuracy of the Xpert® MTB/RIF assay for extra-pulmonary tuberculosis: A meta-analysis. Int J Tuberc Lung Dis 2015;19:278-84, i-iii.